利舒康胶囊治疗非透析CKD肾性贫血的疗效及对其体内氧自由基代谢的影响分析  

Analysis of efficacy of Lishukang capsule on non-dialysis CKD renal anemia and its effect on oxygen free radical metabolism

作　　者：邵淑芹[1] 王晓梅 柳晓明[2] SHAO Shu-qin;WANG Xiao-mei;LIU Xiao-ming(Yantai Laiyang Central Hospital,Yantai 265200,China)

机构地区：[1]烟台市莱阳中心医院,265200 [2]烟台市烟台山医院,234001

出　　处：《中国实用医药》2020年第10期17-19,共3页China Practical Medicine

摘　　要：目的观察利舒康胶囊治疗非透析慢性肾脏病(CKD)肾性贫血的临床疗效及对其体内氧自由基代谢的影响。方法 123例非透析CKD肾性贫血患者,按照随机数字表法分为观察组(62例)和对照组(61例)。对照组患者采用促红细胞生成素(EPO)及补充铁剂治疗,观察组在对照组治疗基础上口服利舒康胶囊治疗。比较两组治疗前后氧自由基代谢指标[血清丙二醛(MDA)、超氧化物歧化酶(SOD)]及肾性贫血指标[红细胞(RBC)、血红蛋白(HGB)、网织红细胞计数(ReT)]变化。结果治疗8周后,两组患者RBC、HGB、ReT均较本组治疗前显著升高,且观察组RBC(5.21±1.42)×1012/L、HGB(86.00±12.80)g/L、ReT(56.90±0.54)×109/L均高于对照组的(4.45±1.09)×1012/L、(79.00±13.10)g/L、(39.50±0.76)×109/L,差异具有统计学意义(P<0.05)。治疗8周后,观察组患者MDA较本组治疗前明显下降, SOD较本组治疗前显著升高,差异具有统计学意义(P<0.05);对照组MDA、SOD与本组治疗前比较差异无统计学意义(P>0.05);观察组患者MDA(3.79±0.74)μmol/L低于对照组的(5.57±0.78)μmol/L,SOD(102.47±18.22)μU/L高于对照组的(91.29±17.41)μU/L,差异具有统计学意义(P<0.05)。结论非透析CKD肾性贫血以西药治疗多数可以纠正,在西药治疗基础上加用利舒康胶囊可一定程度清除氧自由基,维持细胞膜结构完整性,减少对组织脏器结构和功能的破坏,延缓肾功能进行性恶化。Objective To observe the clinical efficacy of Lishukang capsule on non-dialysis chronic kidney disease(CKD) renal anemia and its effect on oxygen free radical metabolism. Methods A total of 123 patients with non-dialysis CKD renal anemia were divided into observation group(62 cases) and control group(61 cases). Patients in the control group were treated with erythropoietin(EPO) and iron supplementation, and patients in the observation group were treated with Lishukang capsules on the basis of the control group. The oxygen free radical metabolism indexes [serum malondialdehyde(MDA), superoxide dismutase(SOD)] before and after treatment and changes of renal anemia indexes [red blood cells(RBC), hemoglobin(HGB), reticulocyte count(ReT)] between the two groups was compared. Results After 8 weeks of treatment, RBC, HGB and ReT in the two groups was significantly higher than those before treatment, and RBC(5.21±1.42)×1012/L, HGB(86.0± 12.8) g/L, ReT(56.9±0.54)×109/L in the observation group were higher than(4.45±1.09)×1012/L,(79.0± 13.1) g/L,(39.50±0.76)×109/L in the control group. Their difference was statistically significant(P<0.05). After 8 weeks of treatment, MDA in the observation group was obviously lower than that before treatment, and SOD was significantly higher than that before treatment. Their difference was statistically significant(P<0.05). In the control group, there was no statistically significant difference in MDA and SOD before and after treatment(P>0.05). MDA(3.79±0.74) μmol/L in the observation group was lower than(5.57±0.78) μmol/L in the control group, and SOD(102.47±18.22) μU/L was higher than(91.29±17.41) μU/L in the control group. Their difference was statistically significant(P<0.05). Conclusion Most of non-dialysis CKD renal anemia can be corrected by Western medicine. The combined use of Lishukang capsule on the basis of Western medicine treatment can eliminate oxygen free radical to a certain extent, maintain the integrity of cell membrane structure, reduce the damage of

关 键 词：利舒康胶囊 慢性肾脏病 肾性贫血 氧自由基 

分 类 号：R692[医药卫生—泌尿科学] R556[医药卫生—外科学]